New Rival to Botox – Reloxin!
Reloxin was developed by a French pharmaceutical firm as a safe and effective alternative to Botox.
Botox has long been the only one source for reducing forehead wrinkles and frown lines among the patients. The drug prevents the contraction of facial muscles, which gives the face a more smooth appearance that lasts for several months.
But now, the French drug inventor – Ipsen may have created a possible rival with its anti-wrinkle treatment, according to recent research. The report can been found in the Archives of Facial Plastic Surgery.
The main difference of Reloxin from Botox is that it contains fewer antigens, less protein in its formula, possibly causing the body to break it down at a slower rate and making it last longer than Botox. In the phase III trials, the Reloxin effects lasted for13 months.
The lead researcher Dr. Ronald Moy from the Moy-Fincher Medical Group in Los Angeles said:
“Reloxin is as safe and it works as well as Botox.”
He also added:
“I think this will be as popular as Botox, which is the most common cosmetic procedure in the United States. Many of our patients are happier and got a more natural look with the use of Reloxin.”
Although Reloxin has not yet been approved in the U.S., it has been approved in 23 countries, and has been in use for over 15 years outside the U.S. to treat neurological disorders.
1,200 patients have undergone the procedure with Reloxin injections in five different areas of the forehead during the study. Research participants were asked to keep diaries of the effects of their treatments and were given post-treatment assessments after one week to 10 days. Participants reported that Reloxin began to work within one day after treatment. After one week, 95 percent of the patients reported a noticeable response to the treatment.
Participants were also assessed after two weeks and one month, with additional assessments following each month after treatment. One month after treatment, about 91 percent of the patients showed a response. Study participants received up to five sets of five injections over the 13-month analysis.
A total of 1,052 patients completed the study with 880 of them experiencing a total of 2,838 adverse events. Of these, only about 28 percent were likely related to the treatment and included problems at the injection site, nervous system disorders such as headache, and eye problems including a drooping of the eyelid or brow known as ptosis. The researchers reported that only one patient withdrew from study due to the side effects of the drug.
Another difference between the two anti-wrinkle medications is that Reloxin spreads out more in the tissue than does Botox, which can be more effective in the forehead areas. But, according to one expert, the drug’s wider spread into the tissue creates a more tedious task for accuracy in the treatment of areas such as crow’s feet near the eyes. Unless an experienced injector delivers the drug, it may spread to surrounding muscles and cause a droopy eyelid or eyebrow.
According to Dr. Ronald Moy:
“It had a good safety profile and was effective, but we did not do a head-to-head comparison (with Botox). That’s the next step, of course, something that probably will be done in the future.”
Botox costs $525 per vial that could treat three to five patients. And in comparison to it, Reloxin costs 15 percent lower.
Our health and beauty are interconnected. Ponder everything over to take a final decision.
Leave a Reply